|Company Profile||Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company that is focused on the acquisition, development, and commercialization of prescription pharmaceutical products. Its portfolio of...||Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases...|
Go to PRTK summary
|Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. It is...|
Go to AQST summary
|Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. The Company is focused on developing and commercializing products in various therapeutic areas, including allergy, opioid...|
Go to ADMP summary
|AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. Its...|
Go to ACRX summary
|P/E (TTM, GAAP)|
|Data as of|
|Total Revenue (TTM)|
(5 year, GAAP)
|Revenue Growth (TTM)|
|Data as of|
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.